[Chronic myeloid leukemia in the 21st century: biology and treatment]
| Autor: | María Antonieta, Chávez-González, Manuel, Ayala-Sánchez, Héctor, Mayani |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Incidence Fusion Proteins bcr-abl Hematopoietic Stem Cell Transplantation Interferon-alpha Antineoplastic Agents Middle Aged Hematopoietic Stem Cells Combined Modality Therapy United States Hematopoiesis Drug Design Leukemia Myelogenous Chronic BCR-ABL Positive Neoplastic Stem Cells Humans Immunologic Factors Mexico Protein Kinase Inhibitors Aged |
| Zdroj: | Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion. 61(3) |
| ISSN: | 0034-8376 |
| Popis: | Chronic Myeloid Leukaemia (CML) is a clonal disease, originated at the level of Hematopoietic Stem Cells (HSC) and characterized by the presence of the Philadelphia (Ph) chromosome and its oncogenic product p210(BcrAbl). Such a protein has been shown to be essential for malignant transformation, since it is capable of altering cell adhesion, proliferation and apoptosis. Historically, CML has been treated by using different approaches: arsenic (in the early days), a variety of chemical agents (busulfan, hydroxyurea, cytarabine), cytokines (IFN-alpha, IFNalpha-PEG), hematopoietic cell transplant (HCT), and more recently drugs generated by design (imatinib, nilotinib, dasatinib). All these molecules exert specific effects on HSC and lead to a variety of clinical and biological responses. In this article, we present an overview about hematopoiesis in CML and its implications in the treatment of this disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|